Literature DB >> 10696069

Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension.

C Chassagne1, S Eddahibi, C Adamy, D Rideau, F Marotte, J L Dubois-Randé, S Adnot, J L Samuel, E Teiger.   

Abstract

Lung vessel muscularization during hypoxic pulmonary hypertension is associated with local renin-angiotensin system activation. The expression of angiotensin II (Ang II) AT1 and AT2 receptors in this setting is not well known and has never been investigated during normoxia recovery. We determined both chronic hypoxia and normoxia recovery patterns of AT1 and AT2 expression and distal muscularization in the same lungs using in situ binding, reverse transcriptase/polymerase chain reaction, and histology. We also used an isolated perfused lung system to evaluate the vasotonic effects of AT1 and AT2 during chronic exposure to hypoxia with and without subsequent normoxia recovery. Hypoxia produced right ventricular hypertrophy of about 100% after 3 wk, which reversed with normoxia recovery. Hypoxia for 2 wk was associated with simultaneous increases (P<0.05) in AT1 and AT2 binding (16-fold and 18-fold, respectively) and in muscularized vessels in alveolar ducts (2. 8-fold) and walls (3.7-fold). An increase in AT2 messenger RNA (mRNA) (P<0.05) was also observed, whereas AT1 mRNA remained unchanged. After 3 wk of hypoxia, muscularization was at its peak, whereas all receptors and transcripts showed decreases (P<0.05 versus hypoxia 2 wk for AT1 mRNA), which became significant after 1 wk of normoxia recovery (P<0.05 versus hypoxia 2 wk). Significant reversal of muscularization (P<0.01) was found only after 3 wk of normoxia recovery in alveolar wall vessels. Finally, the AT1 antagonist losartan completely inhibited the vasopressor effect of Ang II in hypoxic and normoxia-restored lungs, whereas the AT2 agonist CGP42112A had no effect. Our data indicate that in lungs, chronic hypoxia-induced distal muscularization is associated with early and transient increases in AT2 and AT1 receptors probably owing to hypoxia- dependent transcriptional and post-transcriptional regulatory mechanisms, respectively. They also indicate that the vasotonic response to Ang II is mainly due to the AT1 subtype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696069     DOI: 10.1165/ajrcmb.22.3.3701

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  25 in total

1.  Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.

Authors:  Yoriko Yamazato; Anderson J Ferreira; Kwon-Ho Hong; Srinivas Sriramula; Joseph Francis; Masanobu Yamazato; Lihui Yuan; Chastity N Bradford; Vinayak Shenoy; Suk P Oh; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

2.  NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation.

Authors:  Sergio de Frutos; Rhyannon Spangler; Dominique Alò; Laura V González Bosc
Journal:  J Biol Chem       Date:  2007-04-02       Impact factor: 5.157

3.  Effects of olmesartan, an AT1 receptor antagonist, on hypoxia-induced activation of ERK1/2 and pro-inflammatory signals in the mouse lung.

Authors:  Yoshiyuki Tanabe; Yuki Morikawa; Takao Kato; Satoshi Kanai; Taichi Watakabe; Ami Nishijima; Hijiri Iwata; Kaori Isobe; Mayumi Ishizaki; Koichi Nakayama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-07       Impact factor: 3.000

4.  Circulating and Vascular Bioactive Factors during Hypertension in Pregnancy.

Authors:  Alain F Tanbe; Raouf A Khalil
Journal:  Curr Bioact Compd       Date:  2010-03-01

Review 5.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

6.  Increased angiotensin II AT1 receptor mRNA and binding in spleen and lung of AT2 receptor gene disrupted mice.

Authors:  Jaroslav Pavel; José A Terrón; Julius Benicky; Alicia Falcón-Neri; Amita Rachakonda; Tadashi Inagami; Juan M Saavedra
Journal:  Regul Pept       Date:  2009-09-17

7.  Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension.

Authors:  C Agard; M Rolli-Derkinderen; E Dumas-de-La-Roque; M Rio; C Sagan; J P Savineau; G Loirand; P Pacaud
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

8.  Specific single chain variable fragment (ScFv) antibodies to angiotensin II AT(2) receptor: evaluation of the angiotensin II receptor expression in normal and tumor-bearing mouse lung.

Authors:  Masaaki Tamura; Heping Yan; Ofelia Zegarra-Moro; Jennifer Edl; Stephanie Oursler; Cindy Chard-Bergstrom; Gordon Andrews; Tsutomu Kanehira; Susumu Takekoshi; Ray Mernaugh
Journal:  J Mol Histol       Date:  2008-04-28       Impact factor: 2.611

Review 9.  Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Stephanie J Sheppard; Raouf A Khalil
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-03

10.  Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease.

Authors:  Ivan Dimitrijevic; Marie-Louise Edvinsson; Qingwen Chen; Malin Malmsjö; Per-Ola Kimblad; Lars Edvinsson
Journal:  BMC Cardiovasc Disord       Date:  2009-08-25       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.